Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 3Thoracic 2Plasma cell 2Gynecologic 2Genitourinary 2Gastrointestinal 2Breast 2Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Breast Neoplasms 166Triple Negative Breast Neoplasms 54Neoplasm Metastasis 23Pancreatic Neoplasms 16Carcinoma, Non-Small-Cell Lung 15Ovarian Neoplasms 11Colorectal Neoplasms 9Small Cell Lung Carcinoma 8Sarcoma 8Neoplasms 8Lung Neoplasms 8Prostatic Neoplasms 7Colonic Neoplasms 7Breast Neoplasms, Male 7Stomach Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Lymphoma, Non-Hodgkin 5Cholangiocarcinoma 5Head and Neck Neoplasms 4Urinary Bladder Neoplasms 3Recurrence 3Rectal Neoplasms 3Multiple Myeloma 3Melanoma 3Kidney Neoplasms 3Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2

Interventions

Flow Cytometry 5Therapeutics 3Immunologic Techniques 3Amplified Fragment Length Polymorphism Analysis 3ruxolitinib 2pembrolizumab 2abiraterone 2Vorinostat 2Psychiatric Rehabilitation 2Polymerase Chain Reaction 2Ondansetron 2Methylprednisolone 2Immunoenzyme Techniques 2Gemcitabine 2Doxorubicin 2Dexamethasone 2Calcium Dobesilate 2Aprepitant 2Alemtuzumab 2venetoclax 1trametinib 1sargramostim 1rucaparib 1regorafenib 1ponatinib 1pertuzumab 1pemigatinib 1palbociclib 1olaparib 1neratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × Gemcitabine × Breast × Clear all
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Incyte Corporation

Phase 1/2 Terminated
201 enrolled 71 charts
BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡